{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:23Z","timestamp":1792887803708,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","brainanddevelopment.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.braindev.2024.104316","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T04:31:03Z","timestamp":1736310663000},"page":"104316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Motor function and compound muscle action potential amplitude in children with spinal muscular atrophy treated with nusinersen"],"prefix":"10.1016","volume":"47","author":[{"given":"Yingshuang","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxiong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2024.104316_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.braindev.2024.104316_bb0010","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.braindev.2024.104316_bb0015","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","article-title":"Nusinersen for the treatment of spinal muscular atrophy","volume":"17","author":"Chiriboga","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.braindev.2024.104316_bb0020","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2024.104316_bb0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2024.104316_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"Damjan","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2024.104316_bb0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2024.104316_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2024.104316_bb0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","article-title":"CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening","volume":"23","author":"Weng","year":"2021","journal-title":"Genetics in Med"},{"key":"10.1016\/j.braindev.2024.104316_bb0050","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.3390\/pharmaceutics14102074","article-title":"Clinical and electrophysiological changes in pediatric spinal muscular atrophy after 2 years of Nusinersen treatment","volume":"14","author":"Axente","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.braindev.2024.104316_bb0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.nmd.2023.02.004","article-title":"A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy","volume":"33","author":"Barrois","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2024.104316_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X211008725","article-title":"Spinal muscular atrophy: the use of functional motor scales in the era of disease-modifying treatment","volume":"8","author":"Pierzchlewicz","year":"2021","journal-title":"Child Neurol Open"},{"key":"10.1016\/j.braindev.2024.104316_bb0065","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.braindev.2024.104316_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.braindev.2024.104316_bb0075","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mus.26419","article-title":"Revised upper limb module for spinal muscular atrophy: 12month changes","volume":"59","author":"Pera","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.braindev.2024.104316_bb0080","first-page":"36","article-title":"Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2024.104316_bb0085","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.21838","article-title":"Compound muscle action potential and motor function in children with spinal muscular atrophy","volume":"42","author":"Lewelt","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.braindev.2024.104316_bb0090","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1007\/s00415-023-11787-y","article-title":"Biomarkers in 5q-associated spinal muscular atrophy\u2014a narrative review","volume":"270","author":"Lapp","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.braindev.2024.104316_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211035643","article-title":"Update on biomarkers in spinal muscular atrophy","volume":"16","author":"Pino","year":"2021","journal-title":"Biomark Insights"},{"key":"10.1016\/j.braindev.2024.104316_bb0100","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"Pechmann","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.braindev.2024.104316_bb0105","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/jnnp-2020-324532","article-title":"Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions","volume":"92","author":"Chan","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2024.104316_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02547-8","article-title":"Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study","volume":"17","author":"Pechmann","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2024.104316_bb0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.braindev.2024.104316_bb0120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JND-200533","article-title":"Clinical outcomes in patients with spinal muscular atrophy type 1 treated with Nusinersen","volume":"8","author":"de Holanda","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.braindev.2024.104316_bb0125","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type II spinal muscular atrophy pediatric patients treated with nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2024.104316_bb0130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1113\/JP282249","article-title":"Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen","volume":"600","author":"Kariyawasam","year":"2022","journal-title":"J Physiol"},{"key":"10.1016\/j.braindev.2024.104316_bb0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","article-title":"Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen","volume":"92","author":"Kariyawasam","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2024.104316_bb0140","doi-asserted-by":"crossref","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn screening for spinal muscular atrophy in New York state: clinical outcomes from the first 3 years","volume":"99","author":"Lee","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2024.104316_bb0145","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1007\/s00415-020-10332-5","article-title":"Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study","volume":"268","author":"Querin","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.braindev.2024.104316_bb0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2024.104316_bb0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.31083\/j.fbl2706179","article-title":"Physical therapy and nusinersen impact on spinal muscular atrophy rehabilitative outcome","volume":"27","author":"Mirea","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.braindev.2024.104316_bb0160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.arcped.2023.03.006","article-title":"Immunization status of patients with spinal muscular atrophy receiving nusinersen therapy","volume":"30","author":"Ye\u015filmen","year":"2023","journal-title":"Arch Pediatr"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760424001694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760424001694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:44:49Z","timestamp":1740141889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760424001694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0387760424001694"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2024.104316","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Motor function and compound muscle action potential amplitude in children with spinal muscular atrophy treated with nusinersen","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2024.104316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society of Child Neurology. Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104316"}}